drug treatments, new vaccines, and molecular diagnostics, revealed that it has joined the Nasdaq Biotechnology Index® (Nasdaq: NBI) on Monday prior to market opening.
The NBI is a leading international biotechnology equity index that monitors the functioning and productivity of Nasdaq-listed biotechnology and pharmaceutical companies. The NBI is extensively watched and monitored by investors and Exchange Traded Funds products globally since it is calculated using a modified capitalization-weighted approach. Teknova qualified as an NBI firm by meeting numerous criteria, such as a minimum market capitalization, an average daily trading volume, and a period of time listed as a public business.
Stephen Gunstream, President and CEO of Teknova, expressed pride over the company’s accomplishments. He said, “The Teknova team has successfully executed on several important milestones since our Initial Public Offering in June 2021, and I’m proud of their commitment to our mission of accelerating the development and commercialization of next generation therapies, vaccines, and diagnostics. We are honored to join the NBI, which we believe validates our team’s hard work and progress in delivering value to all our stakeholders”.
By supplying specialized products and reagents for bioprocessing, bioproduction, and molecular diagnostics, Teknova is accelerating clinical advancements in the life sciences. Teknova’s innovative techniques support the manufacturing and delivery of high-quality, custom-made-to-order goods quickly and at scale throughout all stages of development, including marketing.
With an emphasis on agility and customization, Teknova develops and manufactures research-grade and GMP products such as cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a variety of well-known and emerging applications such as cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology.
